CRB A4
Alternative Names: CRB-486; CRB-A4Latest Information Update: 15 Feb 2024
At a glance
- Originator Celros Biotech
- Class Anti-inflammatories; Antineoplastics; Hepatoprotectants; Immunotherapies; Monoclonal antibodies
- Mechanism of Action SH3YL1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Diabetic nephropathies; Inflammatory bowel diseases; Liver cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 14 Feb 2024 Preclinical trials in Acute kidney injury in South Korea (Parenteral) prior to February 2024 (Celros Biotech pipeline, February 2024)
- 14 Feb 2024 Preclinical trials in Diabetic nephropathies in South Korea (Parenteral) prior to February 2024 (Celros Biotech pipeline, February 2024)
- 14 Feb 2024 Preclinical trials in Inflammatory bowel diseases in South Korea (Parenteral) prior to February 2024 (Celros Biotech pipeline, February 2024)